Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017
The XV annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) took place in Siena, Tuscany, on October 5–7, 2017. International leading scientists from academic institutions and pharmaceutical companies presented updates on new research achievements in cancer bio-immunotherapy. The meeting aimed to build a close connection between clinical and pre-clinical research. Many topics were discussed during the meeting, such as (a) tumor microenvironment; (b) epigenetics, immune cells and cancer; (c) commensal microorganisms, food, immune cells and cancer; (d) immune agonists and antagonists; (e) active and adoptive immunotherapy; (f) prospective NIBIT and NIBIT Foundation collaborations. There follows a brief summary of the topics discussed in the meeting.
Session 1: tumor microenvironment 1
Growing experimental evidence points to a significant role of the host immune system and its interactions with cancer cells inside the tumor microenvironment (TME) in modulating...
KeywordsImmunotherapy Cancer vaccines Checkpoint blockade agents Targeted therapies NIBIT Tumor microenvironment
Adoptive cell therapy
Chimeric antigen receptors
Cancer stem cells
Disease control rate
Italian society of cytometry
Glucocorticoid-induced tumor necrosis factor receptor
Immune checkpoint inhibitors
Invariant natural killer T cells
Mutations and drugs portal
Myeloid-derived suppressor cells
Non-small cell lung cancer
Objective response rate
Pancreatic ductal adenocarcinoma
Plasmacytoid dendritic cells
Reactive oxygen species
Transgenic T-cell factor 1
Tertiary lymphoid structures
Triple-negative breast cancer
Tumor necrosis factor receptor
Regulatory T cells
This meeting was organized in collaboration with the Board of Directors of NIBIT and with NIBIT Foundation.
Michele Maio, Maria Fortunata Lofiego, Carolina Fazio, Sara Cannito, Carla Chiarucci, Gianluca Giacobini, Alessia Covre contributed to writing the summary of the different meeting sessions; Vincenzo Russo, Monica Valente, Patrizia Tunici, Alessia Covre, and Michele Maio supervised and critically contributed to the final revision of the manuscript.
This meeting was supported in part by grants from Bristol-Meyers Squibb, Incyte, Merck Sharp & Dohme Corp. Oncology, Roche, Astex pharmaceuticals, Amgen, AstraZeneca and Merck Serono.
Compliance with ethical standards
Conflict of interest
Michele Maio is a consultant/advisory board member for Bristol-Meyers Squibb, Incyte, Merck Sharp & Dohme Corp. Oncology, Roche, Astex pharmaceuticals, Amgen, AstraZeneca and Merck Serono. No potential conflicts of interest were disclosed by the other authors.